伴POD24的脾边缘区淋巴瘤临床特征与预后
回顾性分析瑞金医院2009年12月至2022年10月88例初治脾边缘区淋巴瘤(SMZL)患者,10例(11.4%)发生POD24。POD24组总生存期和无进展生存期均短于非POD24组。POD24与组织转化是总生存的独立不良预后因素,初始治疗后未缓解是POD24的独立危险因素。
要点
- 88例SMZL中10例(11.4%)发生POD24,POD24组中位总生存期77个月,非POD24组未达到。
- POD24与组织转化是SMZL总生存的独立不良预后因素。
- 初始治疗后疾病未缓解是影响POD24的独立危险因素。
核心结论
- POD24与组织转化是影响SMZL患者总生存的独立不良预后因素。
- POD24患者发生组织转化的风险高。
- 初始治疗后疾病未缓解是影响POD24患者的独立危险因素。
研究设计与样本
- 回顾性分析2009年12月至2022年10月上海交通大学医学院附属瑞金医院88例初治SMZL患者的临床资料。
- 根据POD24发生情况分组,进行预后评估及临床特征比较。
主要发现
- 男45例(51.1%),女43例(48.9%),诊断时中位年龄59(24~82)岁,10例(11.4%)发生POD24。
- POD24组中位总生存期77(11~159)个月 vs 非POD24组未达到,P<0.001。
- POD24组中位无进展生存期15(4~24)个月 vs 非POD24组121(24~154)个月,P<0.001。
- 单因素Cox分析显示ECOG评分≥2分、aaIPI评分高危、POD24、发生组织转化、初始治疗后疾病未缓解为总生存的影响因素。
- 多因素分析显示POD24与发生组织转化为总生存的独立预后不良因素,初始治疗后疾病未缓解为影响POD24的独立危险因素。
关键数值与推荐
- 单因素Cox分析:ECOG评分≥2分 HR=8.942(95%CI 1.097~72.910),P=0.041。
- 单因素Cox分析:aaIPI评分高危 HR=5.070(95%CI 1.256~20.461),P=0.023。
- 单因素Cox分析:POD24 HR=14.049(95%CI 3.339~59.107),P<0.001。
- 单因素Cox分析:发生组织转化 HR=7.819(95%CI 1.952~31.316),P=0.004。
- 单因素Cox分析:初始治疗后疾病未缓解 HR=6.080(95%CI 1.439~25.690),P=0.014。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics, prognosis, and risk factors associated with disease progression within 24 months (POD24) after diagnosis in patients with splenic marginal zone lymphoma (SMZL) . Methods: Clinical data from 88 newly diagnosed SMZL patients treated at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, between December 2009 and October 2022, were retrospectively analyzed. Patients were grouped based on the presence of POD24 for prognostic evaluation and comparison of clinical features. Results: There were 45 males (51.1% ) and 43 females (48.9% ), with a median age of 59 (24-82) years at the time of diagnosis. Ten (11.4% ) cases occurred POD24. The overall survival (OS) time and progression- free survival (PFS) time in the POD24 group were shorten than non-POD24 group [median OS time: 77 (11-159) months vs not reached, P<0.001; 15 (4-24) months vs 121 (24-154) months, P<0.001]. Univariate Cox analysis showed that Eastern Cooperative Oncology Group (ECOG) score ≥ 2 [HR=8.942 (95% CI 1.097-72.910), P=0.041], age-adjusted International Prognostic Index (aaIPI) score of high-risk [HR=5.070 (95% CI 1.256-20.461), P=0.023], POD24 [HR=14.049 (95% CI 3.339-59.107), P<0.001], occurrence of tissue transformation [HR=7.819 (95% CI 1.952-31.316), P=0.004], and disease unremission status after initial treatment [HR=6.080 (95% CI 1.439-25.690), P=0.014] were the influencing factors for OS in SMZL patients. Multivariate analysis showed that POD24 [HR=5.859 (95% CI 1.249-27.475), P=0.025] and occurrence of tissue transformation [HR=5.520 (95% CI 1.050-29.009), P=0.044] were independent prognostic factors affecting OS. Univariate logistic analysis showed that ECOG ≥ 2 [HR=7.556 (95% CI 1.498-38.110), P=0.014], high risk of aaIPI score [HR=5.500 (95% CI 1.378- 21.945), P=0.016], occurrence of tissue transformation [HR=8.000 (95% CI 1.759-36.383), P=0.007], and disease unremission status after initial treatment [HR=9.136 (95% CI 2.216-37.675), P=0.002] were the influencing factors of POD24. Multifactorial analysis showed that disease unremission after initial treatment [HR=8.253 (95% CI 1.681- 40.518), P=0.009] was an independent risk factor affecting POD24. Conclusions: POD24 and tissue transformation are independent poor prognostic factors for OS in SMZL patients. Patients with POD24 are at a higher risk of developing tissue transformation. The failure to alleviate the disease after initial treatment is an independent risk factor affecting POD24 patients. 目的: 探讨脾边缘区淋巴瘤(splenic marginal zone lymphoma,SMZL)确诊后24个月内疾病进展(POD24)患者的临床特征、预后及危险因素。 方法: 回顾性分析2009年12月至2022年10月在上海交通大学医学院附属瑞金医院就诊的88例初治SMZL患者的临床资料,根据POD24发生情况分组并进行预后评估及临床特征比较。 结果: 男45例(51.1%),女43例(48.9%),诊断时中位年龄59(24~82)岁。10例(11.4%)发生POD24。POD24组总生存(OS)期和无进展生存(PFS)期短于非POD24组[中位OS期:77(11~159)个月对未达到,P<0.001;中位PFS期:15(4~24)个月对121(24~154)个月,P<0.001]。单因素Cox分析显示,美国东部肿瘤协作组(ECOG)评分≥2分[HR=8.942(95% CI 1.097~72.910),P=0.041]、年龄调整的国际预后指数(aaIPI)评分高危[HR=5.070(95% CI 1.256~20.461),P=0.023]、POD24[HR=14.049(95% CI 3.339~59.107),P<0.001]、发生组织转化[HR=7.819(95% CI 1.952~31.316),P=0.004]、初始治疗后疾病未缓解[HR=6.080(95% CI 1.439~25.690),P=0.014]为SMZL患者OS的影响因素。多因素分析显示,POD24[HR=5.859(95% CI 1.249~27.475),P=0.025]、发生组织转化[HR=5.520(95% CI 1.050~29.009),P=0.044]为OS的独立预后不良因素。单因素Logistic分析显示,ECOG评分≥2分[HR=7.556(95% CI 1.498~38.110),P=0.014]、aaIPI评分高危[HR=5.500(95% CI 1.378~21.945),P=0.016]、发生组织转化[HR=8.000(95% CI 1.759~36.383),P=0.007]、初始治疗后疾病未缓解[HR=9.136(95% CI 2.216~37.675),P=0.002]与POD24的发生相关。多因素分析显示,初始治疗后疾病未缓解[HR=8.253(95% CI 1.681~40.518),P=0.009]为影响POD24的独立危险因素。 结论: POD24、发生组织转化为影响SMZL患者OS的独立预后不良因素。POD24患者发生组织转化风险高。初始治疗后疾病未缓解为影响POD24患者的独立危险因素。.
引用
- Wang L, Shi Q, Zhao WL, et al. [Clinical features and prognosis of splenic marginal zone lymphoma with POD24]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40059687. doi:10.3760/cma.j.cn121090-20240729-00285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。